Evidence map›Paper›PMID 40771749›Full record

ArticleJournal of the advanced practitioner in oncology2025

Operationalization and Use of Bispecific T-Cell-Engaging Antibodies in Community Practices: Multidisciplinary Perspectives on Developing Logistics and Workflow for Cytokine Release Syndrome Management.

William Donnellan, Shih-Wen Lin, Jonathan Abbas, Jesus G Berdeja, Lourenia Cassoli, Jason C Chandler, Brannon Flores, Sara Hall, Arliene Ravelo, Anthony Masaquel and 5 more

Abstract read
In one paragraph

Article in Journal of the advanced practitioner in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

William DonnellanFrom Tennessee Oncology, Nashville, Tennessee.
Shih-Wen LinGenentech, Inc., South San Francisco, California.
Jonathan AbbasFrom Tennessee Oncology, Nashville, Tennessee.
Jesus G BerdejaFrom Tennessee Oncology, Nashville, Tennessee.
Lourenia CassoliGenentech, Inc., South San Francisco, California.
Jason C ChandlerWest Cancer Center, Germantown, Tennessee.
Brannon FloresGenentech, Inc., South San Francisco, California.
Sara HallUniversity Cancer & Blood Center, Athens, Georgia.
Arliene RaveloGenentech, Inc., South San Francisco, California.
Anthony MasaquelGenentech, Inc., South San Francisco, California.
Sharifa PattersonFrom Tennessee Oncology, Nashville, Tennessee.
Eileen PengAstera Cancer Care, Edison, New Jersey.
Ashley ToddFrom Tennessee Oncology, Nashville, Tennessee.
Chelsea TraughberFrom Tennessee Oncology, Nashville, Tennessee.
Lisa RaffOneOncology, Chicago, Illinois.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Operationalizing workflows to manage cytokine release syndrome (CRS) in community practices presents challenges for multidisciplinary teams. Real-world experience was gathered from OneOncology community health-care professionals to establish best-prac-tice workflows for CRS management. Methods: Qualitative data were gathered via focus groups from hematology-oncology MDs, PharmDs, and nurse providers ( Results: Three themes were identified: (1) creating a coordinated workflow plan, (2) building network partnerships, and (3) understanding patient support. Workflow decisions were driven by community practices managing patients treated with BsAbs or partnering with sites for initial dosing and maintenance. Catalysts for developing CRS workflows included: FDA approval of BsAbs; BsAbs clinical trial experience; BsAbs on formulary; having patients receiving BsAbs; and practice champion(s) for protocol development. Key steps included defining communication during and after practice hours, designating training leads, and creating practice-specific plans for interdisciplinary team coordination. Inpatient admission processes developed with hospital staff and hospital staff training were fundamental for successful patient management. Communication processes among practice, pharmacy, and hospital staff throughout BsAbs treatment were established, along with methods to ensure the availability of CRS treatment if needed. Continuous patient/caregiver education on BsAbs treatment, monitoring for adverse events (particularly CRS), and how/when to access care were described. Conclusions: BsAb use in community settings requires multidisciplinary coordination between practices and hospitals. Actions included identifying practice champions, establishing clear workflows for transitioning patients between inpatient and outpatient settings, and ensuring continuous training of staff, patients, and caregivers.

Identifiers

PMID40771749
PMCPMC12323733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.